The opioid induced constipation (OIC) drugs market valued for $1,105.71 million in 2021 and is estimated to reach $1,785.01 million by 2031, exhibiting a CAGR of 4.9% from 2022 to 2031. Opioid-induced constipation (OIC) is a common side effect of opioids, which are the class of pain medications. Opioid induced constipation (OIC) occurs when opioids slow down the movement of the muscles in the digestive tract, making it difficult to have a bowel movement. Symptoms of opioid induced constipation (OIC) include infrequent bowel movements, hard stools, and difficulty in passing stools. The opioid induced constipation (OIC) drugs market refers to the various drugs and treatments that are used to manage constipation which is caused by using opioids. Opioid medications such as morphine, codeine, hydrocodone, and others cause constipation.
The major factors driving the growth of opioid induced constipation drugs market are increasing use of opioids for pain management, growing geriatric population and increasing prevalence of opioid induced constipation (OIC). For instance, an article published in National Library of Medicine 2022 reported prevalence of opioid induced constipation (OIC) accounted for 15-81% in 2021, thus driving the growth of market. Further, a rise in geriatric population is expected to contribute to growth of market, as geriatric population are more prone to chronic diseases and pain disorders. For instance, according to a report by the World Health Organization 2022, stated that, number of persons aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion, thus rise in geriatric population is anticipated to drive the growth of market.
In addition, geriatric population are prone pain disorders such as cancer pain which results in an increase in use of opioids, leading to chances of prevalence of constipation. For instance, an article published in National Institute of Health 2021 reported 4-9% of patients aged 65 and older use prescription opioid medications for pain relief across the globe in 2020, thus driving the growth of the market. However, high costs of novel pharmaceuticals to treat opioid induced constipation (OIC) and unfavorable reimbursement policies are probable factors which restrain the growth of market.
Further, rise in R&D activities, rise in regulatory approvals and higher spending for opioid induced constipation (OIC) research are the factors expected to provide lucrative opportunities to key players of the market. In addition, rise in demand for novel therapeutics for treating opioid induced constipation (OIC) is further anticipated to drive the growth of market.
The global opioid induced constipation drugs market is segmented into drug type, prescription type, distribution channel and region. On the basis of drug type, the market is categorized into mu-opioid receptor antagonists, chloride channel-2 activators and others. On the basis of prescription type, the market is categorized into over the counter drugs and prescribed drugs. On the basis of distribution channel, the market is categorized into hospital pharmacies, online providers and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major Key players that operate in the global opioid induced constipation drugs market are AstraZeneca, Bausch Health Companies Inc., Cosmo pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Mallinckrodt plc, Merck & Co., Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Shionogi & Co., Ltd.
The major factors driving the growth of opioid induced constipation drugs market are increasing use of opioids for pain management, growing geriatric population and increasing prevalence of opioid induced constipation (OIC). For instance, an article published in National Library of Medicine 2022 reported prevalence of opioid induced constipation (OIC) accounted for 15-81% in 2021, thus driving the growth of market. Further, a rise in geriatric population is expected to contribute to growth of market, as geriatric population are more prone to chronic diseases and pain disorders. For instance, according to a report by the World Health Organization 2022, stated that, number of persons aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion, thus rise in geriatric population is anticipated to drive the growth of market.
In addition, geriatric population are prone pain disorders such as cancer pain which results in an increase in use of opioids, leading to chances of prevalence of constipation. For instance, an article published in National Institute of Health 2021 reported 4-9% of patients aged 65 and older use prescription opioid medications for pain relief across the globe in 2020, thus driving the growth of the market. However, high costs of novel pharmaceuticals to treat opioid induced constipation (OIC) and unfavorable reimbursement policies are probable factors which restrain the growth of market.
Further, rise in R&D activities, rise in regulatory approvals and higher spending for opioid induced constipation (OIC) research are the factors expected to provide lucrative opportunities to key players of the market. In addition, rise in demand for novel therapeutics for treating opioid induced constipation (OIC) is further anticipated to drive the growth of market.
The global opioid induced constipation drugs market is segmented into drug type, prescription type, distribution channel and region. On the basis of drug type, the market is categorized into mu-opioid receptor antagonists, chloride channel-2 activators and others. On the basis of prescription type, the market is categorized into over the counter drugs and prescribed drugs. On the basis of distribution channel, the market is categorized into hospital pharmacies, online providers and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major Key players that operate in the global opioid induced constipation drugs market are AstraZeneca, Bausch Health Companies Inc., Cosmo pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Mallinckrodt plc, Merck & Co., Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Shionogi & Co., Ltd.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the opioid induced constipation (OIC) drugs market analysis from 2021 to 2031 to identify the prevailing opioid induced constipation (OIC) drugs market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the opioid induced constipation (OIC) drugs market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global opioid induced constipation (OIC) drugs market trends, key players, market segments, application areas, and market growth Strategies.
Key Market Segments
By Drug Type
- Mu-opioid Receptor Antagonists
- Chloride Channel-2 Activators
By Prescription Type
- Over The Counter Drugs
- Prescribed Drugs
By Distribution Channel
- Hospital Pharmacies
- Online Providers
- Drug Store and Retail Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- AstraZeneca plc
- cosmo pharmaceuticals
- Dr. Reddy’s Laboratories Ltd.
- Mallinckrodt plc
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Shionogi & Co., Ltd.
- Bausch Health Companies Inc.
- Merck & Co., Inc.
- Takeda Pharmaceutical Company Limited
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of opioid induced constipation (OIC) cases
3.4.1.2. Rise in administration of opioids for cancer and non-cancer pain
3.4.1.3. Rise in the availability of effective opioid induced constipation (OIC) drugs
3.4.2. Restraints
3.4.2.1. Side effects associated with medications used for opioid induced constipation
3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Mu-opioid Receptor Antagonists
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Chloride Channel-2 Activators
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Over The Counter Drugs
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Prescribed Drugs
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Online Providers
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Drug Store and Retail Pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Drug Type
7.2.3. Market size and forecast, by Prescription Type
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Drug Type
7.2.5.1.3. Market size and forecast, by Prescription Type
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Drug Type
7.2.5.2.3. Market size and forecast, by Prescription Type
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Drug Type
7.2.5.3.3. Market size and forecast, by Prescription Type
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Drug Type
7.3.3. Market size and forecast, by Prescription Type
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Drug Type
7.3.5.1.3. Market size and forecast, by Prescription Type
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Drug Type
7.3.5.2.3. Market size and forecast, by Prescription Type
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Drug Type
7.3.5.3.3. Market size and forecast, by Prescription Type
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Drug Type
7.3.5.4.3. Market size and forecast, by Prescription Type
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Drug Type
7.3.5.5.3. Market size and forecast, by Prescription Type
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Drug Type
7.3.5.6.3. Market size and forecast, by Prescription Type
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Drug Type
7.4.3. Market size and forecast, by Prescription Type
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Drug Type
7.4.5.1.3. Market size and forecast, by Prescription Type
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Drug Type
7.4.5.2.3. Market size and forecast, by Prescription Type
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. Australia
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Drug Type
7.4.5.3.3. Market size and forecast, by Prescription Type
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. India
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Drug Type
7.4.5.4.3. Market size and forecast, by Prescription Type
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Drug Type
7.4.5.5.3. Market size and forecast, by Prescription Type
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Drug Type
7.4.5.6.3. Market size and forecast, by Prescription Type
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Drug Type
7.5.3. Market size and forecast, by Prescription Type
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Drug Type
7.5.5.1.3. Market size and forecast, by Prescription Type
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Drug Type
7.5.5.2.3. Market size and forecast, by Prescription Type
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Drug Type
7.5.5.3.3. Market size and forecast, by Prescription Type
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Drug Type
7.5.5.4.3. Market size and forecast, by Prescription Type
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. AstraZeneca plc
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Bausch Health Companies Inc.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. cosmo pharmaceuticals
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Dr. Reddy’s Laboratories Ltd.
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Mallinckrodt plc
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Merck & Co., Inc.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Novartis AG
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Shionogi & Co., Ltd.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Takeda Pharmaceutical Company Limited
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Teva Pharmaceutical Industries Ltd.
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
List of Tables
Table 01. Global Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 02. Opioid Induced Constipation (Oic) Drugs Market for Mu-Opioid Receptor Antagonists, by Region, 2021-2031 (Revenue, $Million)
Table 03. Opioid Induced Constipation (Oic) Drugs Market for Chloride Channel-2 Activators, by Region, 2021-2031 (Revenue, $Million)
Table 04. Opioid Induced Constipation (Oic) Drugs Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 05. Global Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 06. Opioid Induced Constipation (Oic) Drugs Market for Over the Counter Drugs, by Region, 2021-2031 (Revenue, $Million)
Table 07. Opioid Induced Constipation (Oic) Drugs Market for Prescribed Drugs, by Region, 2021-2031 (Revenue, $Million)
Table 08. Global Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 09. Opioid Induced Constipation (Oic) Drugs Market for Hospital Pharmacies, by Region, 2021-2031 (Revenue, $Million)
Table 10. Opioid Induced Constipation (Oic) Drugs Market for Online Providers, by Region, 2021-2031 (Revenue, $Million)
Table 11. Opioid Induced Constipation (Oic) Drugs Market for Drug Store and Retail Pharmacies, by Region, 2021-2031 (Revenue, $Million)
Table 12. Opioid Induced Constipation (Oic) Drugs Market, by Region, 2021-2031 (Revenue, $Million)
Table 13. North America Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 14. North America Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 15. North America Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 16. North America Opioid Induced Constipation (Oic) Drugs Market, by Country, 2021-2031 (Revenue, $Million)
Table 17. U.S. Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 18. U.S. Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 19. U.S. Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 20. Canada Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 21. Canada Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 22. Canada Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 23. Mexico Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 24. Mexico Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 25. Mexico Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 26. Europe Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 27. Europe Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 28. Europe Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 29. Europe Opioid Induced Constipation (Oic) Drugs Market, by Country, 2021-2031 (Revenue, $Million)
Table 30. Germany Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 31. Germany Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 32. Germany Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 33. France Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 34. France Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 35. France Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 36. UK Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 37. UK Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 38. UK Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 39. Italy Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 40. Italy Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 41. Italy Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 42. Spain Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 43. Spain Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 44. Spain Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 45. Rest of Europe Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 46. Rest of Europe Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 47. Rest of Europe Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 48. Asia-Pacific Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 49. Asia-Pacific Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 50. Asia-Pacific Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 51. Asia-Pacific Opioid Induced Constipation (Oic) Drugs Market, by Country, 2021-2031 (Revenue, $Million)
Table 52. Japan Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 53. Japan Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 54. Japan Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 55. China Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 56. China Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 57. China Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 58. Australia Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 59. Australia Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 60. Australia Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 61. India Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 62. India Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 63. India Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 64. South Korea Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 65. South Korea Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 66. South Korea Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 67. Rest of Asia-Pacific Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 68. Rest of Asia-Pacific Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 69. Rest of Asia-Pacific Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 70. LAMEA Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 71. LAMEA Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 72. LAMEA Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 73. LAMEA Opioid Induced Constipation (Oic) Drugs Market, by Country, 2021-2031 (Revenue, $Million)
Table 74. Brazil Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 75. Brazil Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 76. Brazil Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 77. Saudi Arabia Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 78. Saudi Arabia Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 79. Saudi Arabia Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 80. South Africa Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 81. South Africa Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 82. South Africa Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 83. Rest of LAMEA Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 84. Rest of LAMEA Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021-2031 (Revenue, $Million)
Table 85. Rest of LAMEA Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 86. Astrazeneca PLC: Key Executives
Table 87. Astrazeneca PLC: Company Snapshot
Table 88. Astrazeneca PLC: Product Segments
Table 89. Astrazeneca PLC: Product Portfolio
Table 90. Bausch Health Companies Inc.: Key Executives
Table 91. Bausch Health Companies Inc.: Company Snapshot
Table 92. Bausch Health Companies Inc.: Product Segments
Table 93. Bausch Health Companies Inc.: Product Portfolio
Table 94. Cosmo Pharmaceuticals: Key Executives
Table 95. Cosmo Pharmaceuticals: Company Snapshot
Table 96. Cosmo Pharmaceuticals: Product Segments
Table 97. Cosmo Pharmaceuticals: Product Portfolio
Table 98. Cosmo Pharmaceuticals: Key Strategies
Table 99. Dr. Reddy's Laboratories Ltd.: Key Executives
Table 100. Dr. Reddy's Laboratories Ltd.: Company Snapshot
Table 101. Dr. Reddy's Laboratories Ltd.: Product Segments
Table 102. Dr. Reddy's Laboratories Ltd.: Product Portfolio
Table 103. Mallinckrodt PLC: Key Executives
Table 104. Mallinckrodt PLC: Company Snapshot
Table 105. Mallinckrodt PLC: Product Segments
Table 106. Mallinckrodt PLC: Product Portfolio
Table 107. Merck & Co. Inc.: Key Executives
Table 108. Merck & Co. Inc.: Company Snapshot
Table 109. Merck & Co. Inc.: Product Segments
Table 110. Merck & Co. Inc.: Product Portfolio
Table 111. Novartis AG: Key Executives
Table 112. Novartis AG: Company Snapshot
Table 113. Novartis AG: Product Segments
Table 114. Novartis AG: Product Portfolio
Table 115. Novartis AG: Key Strategies
Table 116. Shionogi & Co. Ltd.: Key Executives
Table 117. Shionogi & Co. Ltd.: Company Snapshot
Table 118. Shionogi & Co. Ltd.: Product Segments
Table 119. Shionogi & Co. Ltd.: Product Portfolio
Table 120. Takeda Pharmaceutical Company Limited: Key Executives
Table 121. Takeda Pharmaceutical Company Limited: Company Snapshot
Table 122. Takeda Pharmaceutical Company Limited: Product Segments
Table 123. Takeda Pharmaceutical Company Limited: Product Portfolio
Table 124. Teva Pharmaceutical Industries Ltd.: Key Executives
Table 125. Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 126. Teva Pharmaceutical Industries Ltd.: Product Segments
Table 127. Teva Pharmaceutical Industries Ltd.: Product Portfolio
List of Figures
Figure 01. Opioid Induced Constipation (Oic) Drugs Market, 2021-2031
Figure 02. Segmentation of Opioid Induced Constipation (Oic) Drugs Market, 2021-2031
Figure 03. Top Investment Pockets in Opioid Induced Constipation (Oic) Drugs Market (2022-2031)
Figure 04. Low Bargaining Power of Suppliers
Figure 05. Low Bargaining Power of Buyers
Figure 06. Low Threat of Substitutes
Figure 07. Low Threat of New Entrants
Figure 08. Low Intensity of Rivalry
Figure 09. Drivers, Restraints and Opportunities: Globalopioid Induced Constipation (Oic) Drugs Market
Figure 10. Opioid Induced Constipation (Oic) Drugs Market, by Drug Type, 2021(%)
Figure 11. Comparative Share Analysis of Opioid Induced Constipation (Oic) Drugs Market for Mu-Opioid Receptor Antagonists, by Country 2021-2031(%)
Figure 12. Comparative Share Analysis of Opioid Induced Constipation (Oic) Drugs Market for Chloride Channel-2 Activators, by Country 2021-2031(%)
Figure 13. Comparative Share Analysis of Opioid Induced Constipation (Oic) Drugs Market for Others, by Country 2021-2031(%)
Figure 14. Opioid Induced Constipation (Oic) Drugs Market, by Prescription Type, 2021(%)
Figure 15. Comparative Share Analysis of Opioid Induced Constipation (Oic) Drugs Market for Over the Counter Drugs, by Country 2021-2031(%)
Figure 16. Comparative Share Analysis of Opioid Induced Constipation (Oic) Drugs Market for Prescribed Drugs, by Country 2021-2031(%)
Figure 17. Opioid Induced Constipation (Oic) Drugs Market, by Distribution Channel, 2021(%)
Figure 18. Comparative Share Analysis of Opioid Induced Constipation (Oic) Drugs Market for Hospital Pharmacies, by Country 2021-2031(%)
Figure 19. Comparative Share Analysis of Opioid Induced Constipation (Oic) Drugs Market for Online Providers, by Country 2021-2031(%)
Figure 20. Comparative Share Analysis of Opioid Induced Constipation (Oic) Drugs Market for Drug Store and Retail Pharmacies, by Country 2021-2031(%)
Figure 21. Opioid Induced Constipation (Oic) Drugs Market by Region, 2021
Figure 22. U.S. Opioid Induced Constipation (Oic) Drugs Market, 2021-2031 ($Million)
Figure 23. Canada Opioid Induced Constipation (Oic) Drugs Market, 2021-2031 ($Million)
Figure 24. Mexico Opioid Induced Constipation (Oic) Drugs Market, 2021-2031 ($Million)
Figure 25. Germany Opioid Induced Constipation (Oic) Drugs Market, 2021-2031 ($Million)
Figure 26. France Opioid Induced Constipation (Oic) Drugs Market, 2021-2031 ($Million)
Figure 27. UK Opioid Induced Constipation (Oic) Drugs Market, 2021-2031 ($Million)
Figure 28. Italy Opioid Induced Constipation (Oic) Drugs Market, 2021-2031 ($Million)
Figure 29. Spain Opioid Induced Constipation (Oic) Drugs Market, 2021-2031 ($Million)
Figure 30. Rest of Europe Opioid Induced Constipation (Oic) Drugs Market, 2021-2031 ($Million)
Figure 31. Japan Opioid Induced Constipation (Oic) Drugs Market, 2021-2031 ($Million)
Figure 32. China Opioid Induced Constipation (Oic) Drugs Market, 2021-2031 ($Million)
Figure 33. Australia Opioid Induced Constipation (Oic) Drugs Market, 2021-2031 ($Million)
Figure 34. India Opioid Induced Constipation (Oic) Drugs Market, 2021-2031 ($Million)
Figure 35. South Korea Opioid Induced Constipation (Oic) Drugs Market, 2021-2031 ($Million)
Figure 36. Rest of Asia-Pacific Opioid Induced Constipation (Oic) Drugs Market, 2021-2031 ($Million)
Figure 37. Brazil Opioid Induced Constipation (Oic) Drugs Market, 2021-2031 ($Million)
Figure 38. Saudi Arabia Opioid Induced Constipation (Oic) Drugs Market, 2021-2031 ($Million)
Figure 39. South Africa Opioid Induced Constipation (Oic) Drugs Market, 2021-2031 ($Million)
Figure 40. Rest of LAMEA Opioid Induced Constipation (Oic) Drugs Market, 2021-2031 ($Million)
Figure 41. Top Winning Strategies, by Year
Figure 42. Top Winning Strategies, by Development
Figure 43. Top Winning Strategies, by Company
Figure 44. Product Mapping of Top 10 Players
Figure 45. Competitive Dashboard
Figure 46. Competitive Heatmap: Opioid Induced Constipation (Oic) Drugs Market
Figure 47. Top Player Positioning, 2021
Figure 48. Astrazeneca PLC: Net Revenue, 2019-2021 ($Million)
Figure 49. Astrazeneca PLC: Revenue Share by Segment, 2021 (%)
Figure 50. Astrazeneca PLC: Revenue Share by Region, 2021 (%)
Figure 51. Bausch Health Companies Inc.: Net Revenue, 2019-2021 ($Million)
Figure 52. Bausch Health Companies Inc.: Revenue Share by Segment, 2021 (%)
Figure 53. Bausch Health Companies Inc.: Revenue Share by Region, 2021 (%)
Figure 54. Cosmo Pharmaceuticals: Net Revenue, 2019-2021 ($Million)
Figure 55. Dr. Reddy's Laboratories Ltd.: Net Revenue, 2019-2021 ($Million)
Figure 56. Dr. Reddy's Laboratories Ltd.: Revenue Share by Segment, 2021 (%)
Figure 57. Dr. Reddy's Laboratories Ltd.: Revenue Share by Region, 2021 (%)
Figure 58. Mallinckrodt PLC: Net Sales, 2019-2021 ($Million)
Figure 59. Mallinckrodt PLC: Revenue Share by Segment, 2021 (%)
Figure 60. Mallinckrodt PLC: Revenue Share by Region, 2021 (%)
Figure 61. Merck & Co. Inc.: Net Revenue, 2019-2021 ($Million)
Figure 62. Merck & Co. Inc.: Revenue Share by Segment, 2021 (%)
Figure 63. Merck & Co. Inc.: Revenue Share by Region, 2021 (%)
Figure 64. Novartis AG: Net Sales, 2020-2022 ($Million)
Figure 65. Novartis AG: Revenue Share by Segment, 2022 (%)
Figure 66. Novartis AG: Revenue Share by Region, 2022 (%)
Figure 67. Shionogi & Co. Ltd.: Net Revenue, 2019-2021 ($Million)
Figure 68. Takeda Pharmaceutical Company Limited: Net Revenue, 2019-2021 ($Million)
Figure 69. Takeda Pharmaceutical Company Limited: Revenue Share by Region, 2021 (%)
Figure 70. Teva Pharmaceutical Industries Ltd.: Net Revenue, 2019-2021 ($Million)
Figure 71. Teva Pharmaceutical Industries Ltd.: Revenue Share by Segment, 2021 (%)
Executive Summary
According to the report titled, 'Opioid Induced Constipation (OIC) Drugs Market,' the opioid induced constipation (OIC) drugs market was valued at $1105.71 million in 2021, and is projected to reach $1785.01 million by 2031, growing at a CAGR of 4.9% from 2022 to 2031.Opioids are a group of drugs that are frequently used to treat chronic and non-cancer pain. However, opioids used for treating pain disorders have side effects such as constipation. In addition, food absorption is slowed down and fluid absorption is increased when opioids bind to receptors in the gut and prolong the time for feces to transit through the digestive system. Thus, lack of fluid in the intestine leads to hardening of stool and constipation.
Key factors driving the growth of the opioid induced constipation (OIC) drugs market are increasing prevalence of chronic pain and the growing use of opioids for pain management. In India, rise in opioid use for pain management is expected to drive the growth of opioid induced constipation (OIC) drugs market. For instance, article published in National Library of Medicine 2020, reported that, in India, 2.1% of total population consumed opioids for pain management which accounts for three times the global average use, thus rise in opioid use results in higher chances of opioid induced constipation (OIC) prevalence, thereby driving the growth of market.
In addition, the aging population and the increasing incidence of cancer are also factors driving the growth of opioid induced constipation (OIC) drugs market. In Italy, high number of geriatric populations is expected to drive the growth of market, owing to higher chances of developing chronic pain disorder which result in use of opioids for pain management. For instance, report of Eurostat Statistics - Europe 2022, stated that, Italy accounts for highest number of geriatric population accounting for 23.5% in 2021, thus driving the growth of market. Further, In China, rapid economic development, rise in research activities regarding opioid induced constipation (OIC) and rise in prevalence of opioid induced constipation (OIC) are the factors expected to drive the growth of market.
In addition, rise in regulatory approval of medications for treating opioid induced constipation (OIC) is expected to drive the growth of market. Further, every year U.S. government spends over $560-635 billion on pain medications which is expected to contribute to growth of market. Moreover, the development of novel drugs and therapies and the increasing demand for effective treatment options are also contributing to the growth of the OIC drugs market.
The market also offers growth opportunities to the key players in the market. Many developing regions such India and Brazil offer lucrative opportunities to key players of opioid induced constipation (OIC) drugs market owing to high population base, increase in demand of novel formulations for treating constipation and increase in healthcare spending. In addition, government sponsored research studies regarding opioid induced constipation (OIC) in various countries and medical tourism fuels the growth of opioid induced constipation (OIC) drugs market.
The global opioid induced constipation drugs market is segmented into drug type, prescription type, distribution channel and region. On the basis of drug type, the market is categorized into mu-opioid receptor antagonists, chloride channel-2 activators and others. On the basis of prescription type, the market is categorized into over the counter drugs and prescribed drugs. On the basis of distribution channel, the market is categorized into hospital pharmacies, online providers and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include AstraZeneca, Bausch Health Companies Inc., Cosmo pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Mallinckrodt plc, Merck & Co., Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Shionogi & Co., Ltd. The players in the market have been actively engaged in the adoption various Strategies such agreement to remain competitive and gain advantage over the competitors in the market. For instance, in February 2021, Cosmo Pharmaceuticals announced an agreement with RedHill Biopharma Ltd. for manufacturing of Movantik designed to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
Key Market Insights
- On the basis of drug type, the mu-opioid receptor antagonist segment was highest contributor to the market in 2021.
- On the basis of prescription type, prescribed drugs segment occupied highest share in 2021 and is expected to remain dominant during forecast period
- On the basis of distribution channel, the drug stores and retail pharmacies segment dominated the market in terms of revenue in 2021. However, the online providers segment is anticipated to grow at the highest CAGR during the forecast period.
- Region wise, North America generated the largest revenue in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- AstraZeneca plc
- cosmo pharmaceuticals
- Dr. Reddy’s Laboratories Ltd.
- Mallinckrodt plc
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Shionogi & Co., Ltd.
- Bausch Health Companies Inc.
- Merck & Co., Inc.
- Takeda Pharmaceutical Company Limited
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
